Group 1 - Shida Shenghua expects a net loss of 52 million to 60 million yuan for the first half of 2025, a year-on-year decrease of 236.64% to 257.66% [1] - ST Zhizhi's vice president Wang Dong resigned for personal reasons, effective immediately upon delivery of the resignation to the board [1] - Haoyuan Pharmaceutical plans to increase capital by 400 million yuan to its wholly-owned subsidiary through a debt-to-equity swap, raising the registered capital from 400 million to 800 million yuan [1] Group 2 - Longxun Co. announced that shareholders and executives plan to reduce their holdings by up to 2% of the company's shares [2] - Aijian Group confirmed it has not engaged in any stablecoin-related business as of now [3] - Yanghe Co.'s chairman Zhang Liandong resigned due to work adjustments, effective immediately [5] Group 3 - Huanwei New Materials announced a stock suspension due to the major matter that may lead to a change in control [5] - Hualing Cable recently won contracts worth 456 million yuan in the power new energy sector, accounting for 10.97% of its audited revenue for 2024 [6] - Aerospace Changfeng plans to publicly transfer 55.45% of its stake in Aerospace Boke [6] Group 4 - Suzhou Planning is planning to acquire control of Dongjin Aerospace Technology, leading to a stock suspension for up to 10 trading days [6] - Yuexiu Capital intends to increase its stake in Yuexiu Real Estate using up to 204.22 million yuan through the Hong Kong Stock Connect [6] - Baichuan Co.'s actual controller and chairman Zheng Tiejiang is under investigation and has received a detention notice [7] Group 5 - XWANDA plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [8] - ST Aowei reported a loss of approximately 25.04 million yuan in inventory due to poor storage by a third party [8] - Yian Technology plans to increase capital by 120 million yuan to its subsidiary, raising its equity stake from 60% to 72.973% [9] Group 6 - Dongli New Science's wholly-owned subsidiary was applied for bankruptcy reorganization by creditors due to insolvency [11] - Bochuang Technology changed its name to Changxin Bochuang Technology, effective July 2, 2025 [14] - Huayang Co.'s controlling shareholder received a notice of administrative penalty from the China Securities Regulatory Commission [15] Group 7 - Hangzhou Thermal Power's shareholders plan to reduce their holdings by up to 4.09% of the company's shares [16] - Guoke Military Industry's two shareholders plan to reduce their holdings by up to 1.81% of the company's shares [17] - Pangu Intelligent's seven shareholders plan to reduce their holdings by up to 1% of the company's shares [19]

Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. has successfully passed the IPO review despite three consecutive years of losses, marking a significant milestone as the first company to benefit from the reactivation of the fifth set of listing standards for unprofitable enterprises on the Sci-Tech Innovation Board [2][3]. Group 1: Company Overview - Heyuan Biotechnology was established in 2006 and focuses on innovative drug research and development, primarily generating revenue from non-core products such as research reagents, with projected revenue of 25.21 million yuan in 2024 [2]. - The company has reported losses of 144 million yuan, 187 million yuan, and 151 million yuan from 2022 to 2024, totaling over 480 million yuan in cumulative losses [2]. Group 2: Product and Technology - The core product, HY1001 (plant-derived recombinant human serum albumin injection), is a first-class new drug that has completed phase III clinical trials and is expected to be the first domestically approved recombinant human serum albumin drug, addressing the current 60% import dependency in China [3]. - The "rice blood-making" technology, which utilizes rice embryo cell expression systems, has been recognized with a national technology invention award and is seen as a unique technological pathway that combines synthetic biology and medicine [3]. Group 3: Market and Regulatory Context - The fifth set of standards for the Sci-Tech Innovation Board appears tailored for companies like Heyuan Biotechnology, requiring a minimum market value of 4 billion yuan and at least one core product approved for phase II clinical trials [3]. - The successful IPO of Heyuan Biotechnology serves as a potential model for other unprofitable enterprises in cutting-edge fields such as artificial intelligence and biomedicine [2]. Group 4: Risks and Challenges - The company faces several risks, including the need to successfully launch its core product and demonstrate its efficacy to capture the anticipated market share [4]. - Ongoing patent disputes with Ventria Bioscience may hinder international sales and could result in significant compensation costs if the company loses the case [9]. - If profitability is not achieved in the future, the quality of information disclosure and communication with investors may pose substantial challenges [9].

深圳市科思科技股份有限公司 第一条 为了进一步完善深圳市科思科技股份有限公司（以下简称"公司"） 法人治理结构，促进公司规范运作，增强公司决策的独立性和科学性，更好地保 护全体股东特别是中小股东的合法权益，根据《中华人民共和国公司法》、《上 市公司章程指引》、《上海证券交易所科创板股票上市规则》（以下简称"《上 市规则》"）、《上海证券交易所上市公司自律监管指引第5号——交易与关联 交易》等法律、法规、规范性文件以及《深圳市科思科技股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，制定本制度。 第二条 公司关联交易应当遵循以下基本原则： （一）符合诚实信用的原则，保证关联交易的合法性、必要性、合理性和公 允性； （二）公司与关联人之间的关联交易应签订书面协议，协议的签订应遵循平 等、自愿、等价、有偿的原则； （三）与关联方有任何利害关系的董事、股东，在就该关联交易相关事项进 行表决时，应当回避； （四）公司董事会应当根据客观标准判断该关联交易是否对公司有利； （五）不得利用关联交易调节财务指标，损害公司利益。 第三条 公司关联交易，是指公司或者其合并报表范围内的子公司等其他主 体与公司关联人之间发生 ...

合作区将重点推动"四新"产业和澳资产业发展 横琴将加强重点产业规模和发展能级来促进澳门经济适度多元发展。 《规划》明确，到2029年澳门回归祖国30周年时，合作区与澳门经济高度协同、规则深度衔接的制度体系全面确立，市场准入制度高效衔接。各类要素跨境 流动高效便捷，电子围网系统和跨境金融管理体系建立健全，货物"一线放开、二线管住"的体系高效运转，人员出入境高度便利。同时，特色产业发展形成 规模，"四新"产业增加值占地区生产总值比重从2024年的59.4%提升至65%。澳资产业增加值从2024年的30.04亿元增加至90亿元。 6月30日，《横琴粤澳深度合作区产业发展规划（2025—2029年）》（下称《规划》）印发，明确了横琴粤澳深度合作区（下称"合作区"）接下来几年时间 里，在重点产业培育、营商环境建设和琴澳产业一体化等方面的发展思路。 "横琴合作区产业发展的前景，跟同澳门展开深度合作有密切关系。"中山大学岭南学院经济学教授林江告诉第一财经，横琴最重要的机遇是通过粤澳深度合 作，来为澳门中小企业提供一个创新升级的机会。 Film B Har Car . I H T = K HU.U. 上海 Tom The F ...

Core Viewpoint - The successful IPO of Wuhan Heyuan Biotechnology Co., Ltd. marks a significant milestone as the first company to pass the listing review under the fifth set of standards for the Sci-Tech Innovation Board since its restart, reflecting the regulatory support for innovative biotech firms [1][3]. Group 1: Company Overview - Wuhan Heyuan Biotechnology, established in 2006, focuses on the "recombinant human albumin" sector, which is considered a blue ocean market [3]. - The company's core product, HY1001 (recombinant human albumin injection), has completed Phase III clinical trials and is expected to receive approval for market launch soon, potentially becoming the first recombinant human albumin drug in China [3]. - Currently, Heyuan's revenue primarily comes from pharmaceutical excipients and research reagents, with its core innovative drug still in development and not yet generating income, leading to a loss [3]. Group 2: Industry Context - As of now, 20 companies have utilized the fifth set of standards for listing on the Sci-Tech Innovation Board, with 19 being innovative drug development firms and 1 in high-end medical device development [4]. - In 2024, these 20 companies collectively generated over 14 billion yuan in revenue, representing a growth of over 40% compared to 2023, with 16 companies achieving revenues exceeding 1 billion yuan, and 4 surpassing 10 billion yuan [4]. - The first quarter of 2025 saw these companies continue their growth trend, achieving a total revenue of 3.78 billion yuan, a year-on-year increase of 29.27% [4]. - From 2018 to the first quarter of 2025, companies under the fifth set of standards have launched 17 new Class 1 drugs, accounting for approximately 12% of the total number of domestic innovative drugs approved during the same period [4]. Group 3: Regulatory Environment - The successful IPO of Heyuan is seen as a practical example of the China Securities Regulatory Commission's policy to enhance the inclusivity and adaptability of the Sci-Tech Innovation Board, particularly in supporting high-quality technology enterprises [3][4]. - The pace of IPO applications on the Sci-Tech Innovation Board has accelerated, with over 30 applications received in the first half of the year, of which more than 70% are from Sci-Tech Innovation Board companies [5].

整理 | GLP1减重宝典内容团队 6月30日，泰德医药在香港交易所正式挂牌上市，由摩根士丹利与中信证券担任联席保荐人。公司H股发行价定为每股30.60港元，总市值达 43.49亿港元。开盘初期，股价一度上涨近4%，触及31.8港元。 | 30.800+ | 国际 国际 | 32.850 今 开 | 30.300 | | --- | --- | --- | --- | | +0.200 +0.65% | 最低 | 28.100 昨 收 | 30.600 | | | 成交额 2.72亿 市盈率TTM 68.29 总市值 - 43.67亿 | | | | 成交量 | 859.38万股 市盈率(静) 201 | 68.29 总股本 | 1.42亿 | | 换手率 | 11.68% 市净率 1 12.69 流通值 1 | | 22.67亿 | | 52周最高 | 32.850 委 比 -- -- | 51.18% 流通股 | 7360万 | | 52周最低 | 28.100 量 比 | -- 振 幅 幅 -- | 15.52% | | 历史最高 | 32.850 股息TTM | -- 股息率TM | | | 历史最低 ...

Group 1 - Yunzhi Voice Technology Co., Ltd. listed on the Hong Kong Stock Exchange on June 30, becoming the "first AGI stock" in Hong Kong [1] - Yunzhi was founded in 2012 and has developed AI solutions based on deep learning models, including its core algorithm model UniCore [1] - The company has received investments from notable institutions such as Sequoia Capital, JD.com, and Qualcomm, with a significant investment from Sichuan Innovation and Entrepreneurship Equity Investment Fund in 2017 [1] Group 2 - Moore Threads submitted its prospectus for listing on the Sci-Tech Innovation Board, focusing on full-function GPU chip development [2] - The company supports various workloads including AI computing acceleration and 3D graphics rendering [2] - Chengdu Ciyuan Guoyi Electronic Information Equity Investment Fund invested in Moore Threads in 2023 [2] Group 3 - Wuhan Heyuan Biotechnology Co., Ltd. is preparing for an IPO on the Sci-Tech Innovation Board, with its core product HY1001 nearing market approval [2] - HY1001 is a new drug that has completed Phase III clinical trials and is under priority review by the National Medical Products Administration [2] Group 4 - Yaoke Ankang Technology Co., Ltd. successfully listed on the Hong Kong Stock Exchange on June 23, with significant investment from the National Investment (Guangdong) Technology Achievement Transformation Venture Capital Fund [5] - The company focuses on innovative drug development for cancer, inflammation, and cardiovascular diseases, with multiple candidates in clinical stages [5] Group 5 - Sichuan Southwest Jiaotong Railway Development Co., Ltd. listed on the Beijing Stock Exchange on June 10, specializing in rail transportation infrastructure safety [6] - The company is recognized as a national-level "little giant" enterprise and is the first IPO project of the Sichuan Science and Technology Investment's Academician Fund [6] - Multiple local funds, including Chengdu Lixin Jingrong Fund, participated in the investment of Jiaotong Railway Development [6]

Core Viewpoint - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. has terminated its acquisition of Nanjing Haina Pharmaceutical Technology Co., Ltd. due to failure to reach consensus on key transaction terms, but it does not expect any adverse impact on its business operations or financial status [1][3]. Company Overview - Chengdu Xian Dao is a rapidly developing biotechnology company focused on new drug research and development, listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board since April 2020 [7]. - The company has experienced revenue fluctuations post-IPO, but has shown stable growth in recent years, with projected revenues of 4.27 billion yuan for 2024, reflecting a year-on-year growth of 14.99% [7]. Financial Performance - Chengdu Xian Dao's revenue from 2020 to 2024 is reported as follows: 2.44 billion yuan, 3.11 billion yuan, 3.30 billion yuan, 3.71 billion yuan, and 4.27 billion yuan, with year-on-year changes of -7.8%, 27.69%, 5.98%, 12.64%, and 14.99% respectively [7]. - The net profit attributable to shareholders for the same period is 640.2 million yuan, 633.8 million yuan, 252.7 million yuan, 407.2 million yuan, and 513.6 million yuan, with year-on-year changes of -46.77%, -1.00%, -60.14%, 61.16%, and 26.13% respectively [7]. Shareholder Activity - Since 2024, Chengdu Xian Dao has faced frequent shareholder reductions, with a total cash-out of 294 million yuan [8]. - Specific instances of share reductions include a 1.20% stake sold for 78.98 million yuan and a 0.50% stake sold for 31.75 million yuan [9]. Nanjing Haina Pharmaceutical Overview - Nanjing Haina is focused on improved innovative drugs and high-end generic drugs, operating under a "CXO + MAH" business model [3]. - The company submitted an IPO application in June 2023, aiming to raise 850 million yuan, but its application was terminated in June 2024 due to the withdrawal of its sponsor [3][4]. Financial Performance of Nanjing Haina - Nanjing Haina's revenue from 2020 to 2023 is reported as follows: 56.82 million yuan, 168 million yuan, 271 million yuan, and 226 million yuan, with a compound annual growth rate of 118.37% from 2020 to 2022 [4]. - The net profit attributable to shareholders for the same period is -28.71 million yuan, 11.57 million yuan, 68.02 million yuan, and 73.18 million yuan [4]. - As of June 30, 2023, Nanjing Haina's undistributed profits stood at -142 million yuan [4]. Sales and Accounts Receivable - Nanjing Haina's sales expenses have increased significantly, with figures of 3.94 million yuan, 14.46 million yuan, 21.88 million yuan, and 15.41 million yuan over the same period, resulting in a sales expense ratio that is nearly double the industry average [5]. - Accounts receivable have also risen sharply, with balances of 3.01 million yuan, 20.33 million yuan, 41.85 million yuan, and 83.49 million yuan, reflecting a compound growth rate of 269.1% from 2020 to 2022 [5].

Group 1 - The core viewpoint of the article is the issuance of measures by the National Healthcare Security Administration and the National Health Commission to support the high-quality development of innovative drugs, particularly encouraging commercial health insurance to expand investment in innovative drugs [1] Group 2 - The measures encourage commercial health insurance companies to provide stable and long-term investment for innovative drug research and development through various means, such as innovative drug investment funds [1] - The initiative aims to cultivate patient capital that supports innovative drugs [1]

格蓝若机器人团队正在进行机器人研发攻关。 长江日报记者徐丹 摄 【开栏的话】 今天，我们迎来中国共产党成立104周年。本报今起推出"英雄城市·先锋有我"专栏，深 入挖掘一批基层党组织和党员立足岗位、干事创业的生动实践和典型事迹，展示全市广大党 员提能力、转作风、拼业绩、比贡献的新气象，为支点建设、转型发展凝聚先锋力量。 □ 长江日报记者徐丹 通讯员顾澳丽 6月30日，武汉格蓝若智能机器人有限公司（以下简称"格蓝若"）实验室内，工程师们 正紧张测试"大壮""小壮"和机器狗。随着项目管理主管陈燕一声令下，机器人稳健迈步，数 据曲线完美吻合，现场响起热烈掌声。 科技创新发展需要党建工作的有力引领。格蓝若党支部秉持"先锋领航"实践和拼搏精 神，短短7个月，让人形机器人实现从0到1的突破，生动践行了科技自立自强的使命担当。 ■ 突击队立下军令状 身高1.8米、体重95公斤，采用自主研发的运动控制算法，可负重40～60公斤并实现直 膝行走……这是格蓝若常务副总经理熊少华带领的格蓝若"党员先锋队"与华中科技大学陈学 东院士团队联合研发的"劳动者"系列机器人，乳名"大壮"。 现在"大壮"已实现独立行走、负重行走、上下楼梯、爬 ...